News und Analysen

Aquestive Therapeutics (NASDAQ:AQST) said it remains on track to resubmit its new drug application for Anaphylm, its epinephrine sublingual film for severe allergic reactions, in the third quarter

• 5 Space Stocks Already Climbing Ahead of the SpaceX IPO

Redwire (NYSE:RDW) reported sharply higher first-quarter 2026 revenue and record backlog, while management said the company is increasing

• 3 Undervalued Dividend Payers For Volatile Market Conditions

Radian Group (NYSE:RDN) said its first quarter of 2026 marked the company’s first reporting period as a “global multi-line specialty

Assembly Biosciences (NASDAQ:ASMB) Chief Medical Officer Anuj Gaggar outlined the company’s virology strategy and upcoming clinical priorities during a Bank of America-hosted discussion

Premier Foods (LON:PFD) said full-year trading profit rose ahead of its upgraded expectations, helped by stronger branded sales in the second half, market share gains and continued growth from its

PACS Group (NYSE:PACS) reported a strong start to 2026, with executives citing higher occupancy, improved skilled mix and continued progress integrating acquired facilities as drivers of

• MarketBeat Week in Review – 9/4 - 9/8

Oshkosh (NYSE:OSK) reported first-quarter 2026 results that came in modestly below its internal expectations, but management maintained its full-year outlook

Orion Office REIT (NYSE:ONL) said its first-quarter results reflected continued progress on leasing, asset sales and balance-sheet management, while its board and management continue to evaluate

• 3 Stocks Ringing in The New Year With Large Buyback Announcements

Olin (NYSE:OLN) executives said the company expects a sharp sequential improvement in second-quarter earnings as higher pricing

• Doximity is the Facebook and LinkedIn of the Medical Community

Doximity (NYSE:DOCS) reported fiscal fourth-quarter revenue above the high end of its guidance and said it is entering what management

Seer (NASDAQ:SEER) reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, with management pointing to population-scale proteomics studies, an expanding publication base and

Precigen (NASDAQ:PGEN) reported a sharp increase in first-quarter 2026 revenue as the company’s first commercial product, PAPZIMEOS, continued its U.S. launch following FDA approval in August 2025

• From Missteps to Momentum: Jack in the Box’s Comeback Plan

Jack In The Box (NASDAQ:JACK) reported lower fiscal second-quarter earnings and same-store sales, while management said trends improved

Amdocs (NASDAQ:DOX) reported fiscal second-quarter 2026 revenue and non-GAAP earnings above the midpoint of its guidance, while newly appointed Chief Executive Officer Shimie Hortig used the

• 3 Lesser-Known Healthcare Names With Major Upside in Store

Sanuwave Health (NASDAQ:SNWV) reported record first-quarter revenue and rising consumables utilization, while management said the advanced

Brenntag (ETR:BNR) said its first-quarter 2026 results reflected a slow start to the year followed by a sharp improvement in March as volatility tied to the crisis in the Middle East lifted pricing

• Why Wyndham Hotels Is The Industry Value Play, An Earnings Story

Atour Lifestyle (NASDAQ:ATAT) reported sharply higher first-quarter revenue for 2026, driven by continued expansion of its hotel

• Cabot Boosting Production In Lithium Battery Chain For EV Market

Orion (NYSE:OEC) raised its full-year earnings outlook after reporting first-quarter adjusted EBITDA that exceeded internal

Caris Life Sciences (NASDAQ:CAI) executives said the company is expanding its commercial reach, product pipeline and biopharma partnerships as it looks to build on recent revenue growth following